Clinical reference Biomarker Directory
Back to directory

LEP

Emerging

Leptin regulates appetite; rare congenital deficiency is treatable with metreleptin replacement therapy.

Also known as Leptin
In plain language

Leptin tells the brain when you're full. A very rare genetic condition causes leptin deficiency and severe childhood obesity, treatable with a replacement hormone drug. This is different from typical obesity, where leptin is actually high but the brain doesn't respond to it properly.

Biomarker & context

Leptin (LEP) is a hormone produced by adipose tissue that regulates appetite and energy balance by signaling satiety to the hypothalamus.

What it indicates

Rare congenital leptin deficiency causes severe early-onset obesity from unchecked appetite; more commonly, leptin is studied as a general marker of adipose tissue mass and metabolic status, though "leptin resistance" (high leptin without appetite suppression) is common in typical obesity.

Diagnosis & clinical testing

Measured via serum immunoassay; congenital leptin deficiency is confirmed via genetic testing (LEP gene mutations) when clinical suspicion is high (extreme early-onset obesity with very low or undetectable leptin, unlike typical obesity where leptin is elevated).

Guiding treatment

Rare congenital leptin deficiency is treated with metreleptin, a recombinant leptin replacement therapy — one of the few situations where a hormone deficiency this specific has its own approved replacement drug, distinct from leptin's much more common role as a general obesity/metabolic research marker where replacement doesn't work due to resistance rather than deficiency.

Clinical significance

One of the few specific hormone deficiencies with its own approved replacement drug (metreleptin).

References
  1. General endocrinology reference literature on congenital leptin deficiency and metreleptin replacement therapy.